Akeso falls 6% as FDA declines ivonescimab U.S. applicationMarket Movers·Nov 20, 2026 at 01:51 AM09926-6.15%
JP Morgan maintains BeOne Medicines at Overweight, raises price target to $460 from $445TradingView·Nov 19, 2026 at 06:35 PMONC-0.97%
Citi: 2026 NRDL Negotiation Results Released; Drugmakers Say Price Cuts Mild and ManageableAASTOCKS News·Nov 19, 2026 at 08:06 AMHCM-3.86%01093-3.37%
STOCKS | Hedge Funds Add Alibaba and Futu as Stanley Druckenmiller’s Family Office Exits BaiduCoinLive·Nov 18, 2026 at 08:03 PMBZ-1.50%FUTU+4.84%
CLSA Remains Positive on China's Biopharmaceutical Sector, Prefers INNOVENT BIO and SKB BIOAASTOCKS News·Nov 18, 2026 at 07:58 AM01801-6.03%
CMBI Cuts AKESO TP to HKD99.34; HARMONi-3 Remains Key CatalystAASTOCKS News·Nov 18, 2026 at 05:48 AM09926-6.15%
Innovent Biologics (IVBXF) Receives a Buy from Huatai SecuritiesTip Ranks·Nov 18, 2026 at 05:05 AM01801-6.03%
CMBI Raises SBP GROUP TP to HKD9 as Multiple Innovative Drugs Included in National Medical InsuranceAASTOCKS News·Nov 18, 2026 at 04:23 AM01177-4.01%
If You Invested $100 In BeOne Medicines Stock 10 Years Ago, You Would Have This Much Todaybenzinga_article·Nov 17, 2026 at 10:00 PMONC-0.97%